- Home
- LGI vs IVVD Comparison
LGI vs IVVD Comparison
Compare LGI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | IVVD |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | 122 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.7M | 219.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LGI | IVVD |
|---|---|---|
| Price | $17.26 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 30.1K | ★ 4.4M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $15.32 | $0.53 |
| 52 Week High | $19.88 | $3.07 |
Technical Indicators
Market Signals| Indicator | LGI | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | N/A |
| Support Level | $17.27 | N/A |
| Resistance Level | $17.92 | N/A |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 25.91 | 0.00 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About IVVD Invivyd Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.